Clinical Trial Update: Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE). [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Tiprogrel (THRIVE) in high-risk acute ischemic stroke patients; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Tiprogrel (Tiprogrel)

Snippet

Sponsor: Tianjin Institute of Pharmaceutical Research Co., Ltd | Conditions: Ischemic Stroke | Phase 2 | Status: RECRUITING